Latest Lamivudine Stories

2014-08-25 08:28:30

Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information. Please click: http://www.multivu.com/players/English/7197331-viiv-healthcare-vhc-triumeq-fda-approval LONDON, Aug. 25, 2014 /PRNewswire/ -- On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-05-21 12:16:10

IQWiG Added benefit based on fewer side effects / no data for adolescents and pretreated adults who do not require integrase inhibitors Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality...

2014-04-18 23:04:22

Markets Research Reports.biz added deep and professional market research reports on "HIV Therapeutics Market To 2019" Industry Analysis and Overview. Visit: http://www.marketresearchreports.biz/analysis/193009 (PRWEB) April 18, 2014 The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress...

2013-07-01 15:03:01

Immediate, expanded, and improved treatments needed for infants and toddlers with HIV The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, and will mean that more children will be on better treatments. The Drugs for Neglected Diseases initiative (DNDi) applauds the new guidelines and, with Cipla Ltd. and other partners,...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.